ResMed stock slips as Q4 revenue rose 9%

ResMed Inc. (US7611521078) traded at $220.87 as of August 18, 2026, after a 0.23% rise on the latest quoted session, with a market value of $32.04 billion and a 52-week range of $180.26 to $293.81. The shares are still digesting fiscal 2026 Q4 results that showed revenue of $1.5 billion and non-GAAP EPS of $2.95.

Fiscal 2026 numbers

The latest quarterly report, published on August 6, 2026, also showed revenue up 9% year over year, while full-year fiscal 2026 revenue reached $5.653 billion and free cash flow topped $1.65 billion. That gives the stock a clear valuation anchor: the quoted P/E is 21.22, while the forward P/E is 18.69.

For investors, the most relevant comparison is the mix between growth and payout. ResMed lifted its dividend to $0.66, the ex-dividend date is August 20, 2026, and the annualized payout yield is 1.09% on the quoted profile.

Board changes and outlook

A recent company release said Carol Burt will become lead director on November 15, 2026, while Ron Taylor plans to retire after 21 years on the board. The move adds governance detail to a session that also features analyst commentary and a consensus target of $240.17.

The company's latest profile data put trailing revenue at $5.65 billion, net income at $1.52 billion, and diluted EPS at $10.25. That combination keeps the focus on how much of the fiscal 2026 growth can carry into fiscal 2027.

Sleep therapy core

ResMed's sleep apnea portfolio still does the heavy lifting, led by CPAP devices, masks and connected platforms that support remote monitoring and patient adherence. The business also spans ventilators and software tools for home care providers, which matters because the revenue base is split across devices and digital workflows.

Shares and valuation

ResMed stock remains within striking distance of the 52-week high of $293.81, but it is also sitting well above the 52-week low of $180.26. In other words, the market is pricing in growth, but not at the levels seen earlier in the year.